In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
16 authors.
Anna RomanovDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.ORCID 0000-0002-1239-4946 Grant A KnappeDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.ORCID 0000-0002-5041-2383 Larance RonsardRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, United States.ORCID 0000-0002-5307-1940 Heikyung SuhKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.ORCID 0000-0003-0787-298X Marjan OmerDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.ORCID 0000-0002-7557-5664 Asheley P ChapmanDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.ORCID 0000-0001-8323-5494 Vanessa R LewisKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.ORCID 0009-0006-6077-8975 Katie SpivakovskyDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.ORCID 0009-0001-7766-6535 Josue CanalesDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, United States.
Boris ReizisDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, United States.ORCID 0000-0003-1140-7853 Ryan D TingleDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, United States.ORCID 0000-0003-2874-7010 Christopher A CottrellDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, United States.ORCID 0000-0002-3364-3083 Torben SchiffnerDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, United States.ORCID 0000-0001-6772-8870 Daniel LingwoodRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, United States.ORCID 0000-0001-5631-9238 Mark BatheDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.ORCID 0000-0002-6199-6855 Darrell J IrvineDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.ORCID 0000-0002-8637-1405 Funding
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ARTHUR Y KIM · 2004 to 2026
$94.4MVIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9MTOXICOLOGY CORE UNITP30ES002109 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI NILES, JACQUIN C · 1985 to 2020
$25.6MInvestigation of Synthetic DNA-based Viral Particles for Spatially Controlled Antigen PresentationR01AI162307 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Mark Bathe, Facundo Damian Batista · 2021 to 2026
$2.4MTriggering germline-encoded broadly neutralizing antibody responses against influenza virusR01AI153098 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BATISTA, FACUNDO DAMIAN, LINGWOOD, DANIEL · 2020 to 2023
$2.1MSystemic coordination of pro-inflammatory immune reactions through dendritic cell-restricted sIL6R biogenesisR01AI155447 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2021 to 2025
$2.0MNCI NIH HHS P30 CA014051NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI153098NIAID NIH HHS R01 AI155447NIAID NIH HHS R01 AI162307NIEHS NIH HHS P30 ES002109
6 · The paper itselfAbstract
Recruitment and expansion of rare precursor B cells in germinal centers (GCs) is a central goal of vaccination to generate broadly neutralizing antibodies (bnAbs) against challenging pathogens such as HIV. Multivalent immunogen display is a well-established method to enhance vaccine-induced B cell responses, typically accomplished by using natural or engineered protein scaffolds. However, these scaffolds themselves are targets of antibody responses, with the potential to generate competitor scaffold-specific B cells that could theoretically limit expansion and maturation of "on-target" B cells in the GC response. Here, we rationally designed T-independent, DNA-origami based virus-like particles (VLPs) with optimal antigenic display of the germline targeting HIV Env immunogen, eOD-GT8, and appropriate T cell help to achieve a potent GC response. In preclinical mouse models, these DNA-VLPs expanded significantly higher frequencies of epitope-specific GC B cells compared with a state-of-the-art clinical protein nanoparticle. Optimized DNA-VLPs primed germinal centers focused on the target antigen and rapidly expanded subdominant broadly neutralizing antibody precursor B cells for HIV with a single immunization. Thus, avoiding scaffold-specific responses augments priming of bnAb precursor B cells, and DNA-VLPs are a promising platform for promoting B cell responses towards challenging subdominant epitopes.
Identifiers
PMID40060683
PMCPMC11888200
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390